Abstract 413P
Background
In Asia, ∼40% of patients (pts) with non-small cell lung cancer (NSCLC) are epidermal growth factor receptor-mutation (EGFRm) positive. T790M mutation occurs in ∼50% of pts who develop resistance to a first-/second-generation (1G/2G) EGFR-tyrosine kinase inhibitor (TKI). To investigate prevailing treatment patterns and T790M testing practices in pts with EGFRm locally advanced/metastatic NSCLC treated with first-line (1L) 1G/2G EGFR-TKI, real-world (RW) data were obtained from pts in South Korea.
Methods
Retrospective, non-interventional medical record review of pts with EGFRm NSCLC treated with 1L 1G/2G EGFR-TKIs in routine practice settings between 1 Jan 2015–31 Dec 2017 (follow up: end 2019). Study endpoints: demographic/disease characteristics, 1L EGFR-TKI therapy selection, T790M mutation testing and second-line (2L) therapy selection.
Results
235 pts were included: median age 70 (40–93) years, 63% female, and 64% never smoked. At initial NSCLC diagnosis, 89% of pts had metastatic disease, 63% had an ECOG PS score of 0/1; 57% were ex19del positive. 1L 1G/2G EGFR-TKI therapy: 45% afatinib; 43% gefitinib; 13% erlotinib. 164/235 pts (70%) progressed on 1L therapy; median treatment duration of 10.3 months (mo; range: 0.1–37.2). 71/235 pts (30%) did not progress: 37 (16%) remained on 1L therapy and 34 (14%) discontinued 1L therapy before end of follow-up. 22/235 (9%) died during/after 1L therapy without receiving 2L therapy. Following progression, 68% (n=111/164) were tested for T790M, 43% (n=48/111) were T790M positive; 88% (n=42/48) of those received osimertinib. Overall, 120/164 (73%) received 2L therapy – mainly pemetrexed (n=49; 41%).
Conclusions
In this study, of pts who progressed on 1L 1G/2G EGFR-TKI, 27% did not receive 2L therapy, while only 68% were T790M tested; 88% of positive pts received osimertinib. Suboptimal rates of mutation testing and use of recommended 2L therapies may reflect the fact osimertinib was not reimbursed in South Korea until Dec 2017.
Clinical trial identification
Editorial acknowledgement
Louise Prince, PhD of Ashfield Healthcare Communications, part of UDG Healthcare plc, who provided medical writing support funded by AstraZeneca, Cambridge, UK, the manufacturer of osimertinib, in accordance with Good Publications Practice (GPP3) guidelines.
Legal entity responsible for the study
AstraZeneca.
Funding
AstraZeneca.
Disclosure
Y-C. Kim: Honoraria (institution), Research grant/Funding (self): AstraZeneca; Honoraria (self), Research grant/Funding (self): Roche; Honoraria (self), Research grant/Funding (self): Boehringer Ingelheim. K. Davis: Research grant/Funding (institution), Full/Part-time employment, Employee of RTI Health Solutions, which has received contract research funding from AstraZeneca for my participation in the conduct of the currently submitted study/abstract: RTI Health Solutions; Research grant/Funding (self): Novartis; Research grant/Funding (self): Pfizer; Research grant/Funding (self): Vertex; Research grant/Funding (self): Eli Lilly; Research grant/Funding (self): Eisai. S.P. Nagar: Full/Part-time employment: RTI Health Solutions. W. Sawyer: Full/Part-time employment, I am an independent statistical contractor working for AstraZeneca. N. Yu: Full/Part-time employment: AstraZeneca. A. Taylor: Shareholder/Stockholder/Stock options, Full/Part-time employment: AstraZeneca. All other authors have declared no conflicts of interest.
Resources from the same session
348P - Anti-VEGF inhibitors and renal safety in onco-nephrology consortium: Urinary protein/creatinine ratio (VERSiON UP study)
Presenter: Michio Nakamura
Session: e-Poster Display Session
349P - Proteinuria in patients treated with ramcirumab increases the risk of renal dysfunction
Presenter: Kenta Hayashino
Session: e-Poster Display Session
350P - Rheumatologic immune related adverse events (irAEs) secondary to immune checkpoint inhibitor (ICI) therapy: A Western Australia experience
Presenter: Azim Khan
Session: e-Poster Display Session
351P - Valvular heart diseases in patients treated for breast cancer
Presenter: Ekaterina Kushnareva
Session: e-Poster Display Session
352P - Reproductive system disorders following chemotherapy in patients with breast cancer in Yogyakarta, Indonesia
Presenter: Irfan Haris
Session: e-Poster Display Session
353P - Survey for geriatric assessment in practising oncologists in India
Presenter: Vikas Talreja
Session: e-Poster Display Session
354P - Knowledge, perception, and attitude of oncology-related healthcare providers on complementary and alternative medicine (CAM)
Presenter: Chih Kiang Tan
Session: e-Poster Display Session
355P - Impact of comorbidities and rurality on treatment commencement, completion and outcomes, and health related quality of life, for geriatric oncology patients: Preliminary findings from a regional Australian study
Presenter: Mathew George
Session: e-Poster Display Session
357P - Comparison between immunotherapy and chemotherapy as neoadjuvant setting in resectable non-small cell lung cancer: A systematic review and meta-analysis of prospective trials
Presenter: Chao Zhang
Session: e-Poster Display Session
358P - Adjuvant tyrosine kinase inhibitors in non-squamous non-small cell lung cancer with EGFR driver mutations: An updated meta-analysis of randomized trials
Presenter: Joanmarie Balolong-Garcia
Session: e-Poster Display Session